tiprankstipranks
Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (BR:I1NC34)
:I1NC34
Brazil Market
I1NC34
Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh
RESEARCH TOOLSreports

Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (I1NC34) Price & Analysis

― Followers

I1NC34 Stock Chart & Stats

R$308.14
R$2.48(0.81%)
―
--
Day’s Range― - ―
52-Week RangeR$0.01 - R$337.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)41.00
Market Cap
R$122.97B
Enterprise ValueR$98.65K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)14809.1
Beta0.08
Next Earnings
Nov 03, 2026
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding202,697,740
10 Day Avg. Volume15
30 Day Avg. Volume41
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh News

Incyte price target raised to $137 from $121 at Mizuho
Incyte price target raised to $137 from $121 at Mizuho
Mizuho raised the firm’s price target on Incyte (INCY) to $137 from $121 and keeps an Outperform rating...
2d ago
INCY
Incyte price target raised to $155 from $131 at Leerink
Incyte price target raised to $155 from $131 at Leerink
Leerink analyst Andrew Berens raised the firm’s price target on Incyte (INCY) to $155 from $131 and keeps...
3d ago
INCY
Incyte price target raised to $120 from $110 at JPMorgan
Incyte price target raised to $120 from $110 at JPMorgan
JPMorgan raised the firm’s price target on Incyte (INCY) to $120 from $110 and keeps a Neutral rating...
7d ago
INCY
Damora Therapeutics price target raised to $40 from $35 at Wedbush
Damora Therapeutics price target raised to $40 from $35 at Wedbush
Wedbush raised the firm’s price target on Damora Therapeutics (DMRA) to $40 from $35 and keeps an Outperform...
7d ago
DMRA
INCY
Incyte price target raised to $109 from $99 at RBC Capital
Incyte price target raised to $109 from $99 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Incyte (INCY) to $109 from $99 and...
8d ago
INCY
Incyte price target raised to $130 from $112 at BMO Capital
Incyte price target raised to $130 from $112 at BMO Capital
BMO Capital raised the firm’s price target on Incyte (INCY) to $130 from $112 and keeps a Market...
8d ago
INCY
Incyte price target raised to $150 from $136 at Guggenheim
Incyte price target raised to $150 from $136 at Guggenheim
Guggenheim raised the firm’s price target on Incyte (INCY) to $150 from $136 and keeps a Buy rating...
8d ago
INCY
Incyte price target raised to $119 from $104 at Morgan Stanley
Incyte price target raised to $119 from $104 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Incyte (INCY) to $119 from $104 and keeps an Equal...
8d ago
INCY
Incyte says EC approves Opzelura cream for treatment of AD
Incyte says EC approves Opzelura cream for treatment of AD
Incyte (INCY) announced that the European Commission has approved Opzelura cream for the treatment of moderate atopic dermatitis...
8d ago
INCY
Incyte price target raised to $140 from $136 at BofA
Incyte price target raised to $140 from $136 at BofA
BofA raised the firm’s price target on Incyte (INCY) to $140 from $136 and keeps a Buy rating...
8d ago
INCY
Analyst Reiterates Buy on Opzelura Strength, Keeps 12-Month Price Target Unchanged at $150
Analyst Reiterates Buy on Opzelura Strength, Keeps 12-Month Price Target Unchanged at $150
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Incyte. The associated price target remains...
3d ago
INCY
Incyte Rally Caps Near-Term Upside; Ashwani Verma Reiterates Hold With Unchanged $113 Price Target
Incyte Rally Caps Near-Term Upside; Ashwani Verma Reiterates Hold With Unchanged $113 Price Target
Ashwani Verma, an analyst from UBS, maintained the Hold rating on Incyte. The associated price target remains the...
8d ago
INCY

I1NC34 FAQ

What was Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s price range in the past 12 months?
Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh lowest stock price was R$0.01 and its highest was R$337.80 in the past 12 months.
    What is Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s market cap?
    Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s market cap is R$122.97B.
      When is Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s upcoming earnings report date?
      Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s upcoming earnings report date is Nov 03, 2026 which is in 89 days.
        How were Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s earnings last quarter?
        Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh released its earnings results on Jul 28, 2026. The company reported R$0.007 earnings per share for the quarter, beating the consensus estimate of N/A by R$0.007.
          Is Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh overvalued?
          According to Wall Street analysts Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh pay dividends?
            Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh does not currently pay dividends.
            What is Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s EPS estimate?
            Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh have?
            Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh has 202,697,740 shares outstanding.
              What happened to Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh’s price movement after its last earnings report?
              Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh reported an EPS of R$0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh?
                Currently, no hedge funds are holding shares in BR:I1NC34
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Incyte Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (I1NC34) Earnings & Revenues

                  Historic Earnings Reports
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  B1NT34
                  BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR
                  ―
                  ―
                  BIIB34
                  Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs
                  ―
                  ―
                  M1RN34
                  Moderna, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh
                  ―
                  ―
                  N1BI34
                  Neurocrine Biosciences, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.05 Sh
                  ―
                  ―
                  U2TH34
                  United Therapeutics Corporation Unsponsored Brazilian Depositary Receipt Repr 0.05
                  ―
                  ―
                  Compare BR:I1NC34 Stocks >
                  Popular Stocks